These are the 8 Most Promising Candidates for the COVID-19 Vaccine in the World

This candidate vaccine (mRNA-1273), developed by US biotech company Moderna and the National Institute of Allergy and Infectious Diseases (NIAID). this vaccine is the first vaccine tested on humans in the US.

The Moderna vaccine relies on technology that has never been used in other vaccines at this time, namely using genetic material called messenger RNA (mRNA).

Traditional vaccines consist of an attenuated or inactive virus, or proteins from the virus, to trigger an immune response. In contrast, the mRNA vaccine consists of genetic material that teaches cells to build these viral proteins on their own.

According to National GeographicThis mRNA vaccine has several advantages, including being faster and easier to manufacture than traditional vaccines. Traditional vaccines take a long time to develop because scientists have to grow and deactivate entire pathogens or proteins.

Apart from having advantages, this vaccine also has weaknesses with stability, rapid damage and the possibility to limit immunity.

On July 14, Moderna published promising preliminary results of a 45-participant phase 1 trial in The New England Journal of Medicine, in which all participants developed neutralizing antibodies at levels above the same average as those found in COVID-19 patients. who recovered.

The vaccine appears to be safe and generally well tolerated, but more than half of the participants had some side effects such as fatigue, chills, headaches, muscle aches and pain at the injection site.

In April, HHS, under Operation Warp Speed, committed to spend up to $ 483 million (Rp 7,215,150,600,000) to accelerate Moderna’s vaccine development. This mRNA vaccine can be a promising alternative if it is better developed.

– .